Cargando…
1297. Characteristics for PrEP Uptake, Retention, and Discontinuation: Data From the ANCHOR Study
BACKGROUND: People who inject drugs (PWID) have an increased risk for HIV, and HCV infection may foreshadow HIV acquisition in current epidemics. Studies of PWID have demonstrated a desire to obtain HCV treatment; however, use of pre-exposure prophylaxis (PrEP) in this population has not been well s...
Autores principales: | Mathur, Poonam, Kattakuzhy, Sarah, Nussdorf, Laura, Hill, Kristi, Silk, Rachel, Gross, Chloe, Akoth, Elizabeth, Sidique, Nadeera, Chaudhury, Chloe, Sternberg, David, Masur, Henry, Kottilil, Shyam, Rosenthal, Elana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252394/ http://dx.doi.org/10.1093/ofid/ofy210.1130 |
Ejemplares similares
-
PrEP Indications and PrEP Knowledge, Access, and Interest Among Individuals With HCV
por: Hill, Kristi C, et al.
Publicado: (2022) -
Longterm Evaluation of Hemoglobin A1c Following Hepatitis C Therapy in Patients with and without HIV Co-infection
por: Chaudhury, Chloe, et al.
Publicado: (2017) -
2897. Collocated Buprenorphine Is Associated with Improved HCV Visit Adherence in People Who Inject Drugs (PWID): Data From the ANCHOR Study
por: Rosenthal, Elana S, et al.
Publicado: (2019) -
2900. High Rates of Experienced and Witnessed Opioid Overdose in PWID Receiving HCV Treatment: Data From the ANCHOR Study
por: Rosenthal, Elana S, et al.
Publicado: (2019) -
859. Suboptimal Uptake, Retention, and Adherence of Daily Oral PrEP Among People with OUD Receiving HCV Treatment
por: Brokus, Christopher J, et al.
Publicado: (2021)